Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysiswww.prnewswire.com • almost 7 years ago---
- '"Model results present evidence that abuse-deterrent formulations of extended-release
morphine, such as ARYMO ER, may be associated with fewer abuse-related emergency
department visits, outpatient visits, hospitalizations, substance abuse treatments,
injection-related diseases and deaths," said Alan G. White, Ph.D., managing principal
of the Analysis Group and author of the data presented.'
- ARYMO ER is indicated for the management of pain severe enough to require daily,
around-the-clock, long-term opioid treatment and for which alternative treatment
options are inadequate.
- 'ARYMO ER is contraindicated in patients with: significant respiratory depression;
acute or severe bronchial asthma in an unmonitored setting or in the absence of
resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs)
or use within the last 14 days, known or suspected gastrointestinal obstruction,
including paralytic ileus; hypersensitivity (e.g., anaphylaxis) to morphine.'
- 'Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants : Profound
sedation, respiratory depression, coma, and death may result from the concomitant
use of ARYMO ER with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine
sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics,
antipsychotics, other opioids, alcohol).'
- 'Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease
or in Elderly, Cachectic, or Debilitated Patients : The use of ARYMO ER in patients
with acute or severe bronchial asthma in an unmonitored setting or in the absence
of resuscitative equipment is contraindicated.'